Literature DB >> 1984070

Highly sensitized patients with delayed graft function: a management protocol.

D P Hickey1, C A Vivas, M L Jordan, W B Lopatin, R Hrebinko, R O'Donovan, T R Hakala.   

Abstract

The postoperative management of the highly sensitized renal transplant recipient with delayed graft function on cyclosporine is complicated. Allografts with delayed graft function are reported to have a 20 to 30% poorer 1-year survival than allografts without delayed graft function. Several factors may be implicated in this poorer 1-year survival. A decrease in or cessation of cyclosporine dosage frequently is used in an attempt to minimize nephrotoxicity. Such under-immunosuppression can result in irreversible rejection. Occasionally, a pessimistic view of the prognosis for the transplant may result in early abandonment of the allograft with discontinuation of immunosuppression and allograft nephrectomy. We report on 3 highly sensitized patients whose kidneys had delayed graft function and were deliberately maintained on high doses of cyclosporine throughout the period of delayed graft function. Each graft achieved function (2, 4 and 5 months) after transplantation. The serum creatinine levels 20, 28 and 38 months after transplantation were 2.7, 2.0 and 1.0 mg./dl., respectively. We suggest that the maintenance of high cyclosporine levels throughout the delayed graft function period is useful in highly sensitized recipients and was an important factor in their successful outcome. A management protocol for such patients is proposed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1984070     DOI: 10.1016/s0022-5347(17)38268-x

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  2 in total

Review 1.  BCG immunotherapy for superficial bladder cancer.

Authors:  C R Lockyer; D A Gillatt
Journal:  J R Soc Med       Date:  2001-03       Impact factor: 5.344

Review 2.  Kidney transplantation in highly sensitized patients: reappraisal of etiology, evaluation, and management protocols.

Authors:  R Indudhara; R B Khauli
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.